Skip to main content
. 2015 Jan;104(1):32–43. doi: 10.5935/abc.20140173

Figure 3.

Figure 3

Cost-effectiveness acceptability curves of alternative scenarios (secondary prevention and 10% to 20% ten-year risk primary prevention), where statin prices were fixed at the retail sales prices of the drugs. The curves show the probabilities that the various statin doses would be cost-effective at varying threshold costeffectiveness values.